Chinese Premier Li Keqiang Visits WuXi PharmaTech's Headquarter in Shanghai
SHANGHAI, April 1, 2013 /PRNewswire/ -- Chinese Premier Li Keqiang visited WuXi PharmaTech's headquarter in Shanghai on March 28, 2013. The visit was part of the first research tour by the newly elected Chinese Premier since assuming office in March 2013.
Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, accompanied Premier Li on the tour of research laboratories. "We are very excited to host Premier Li at WuXi," said Dr. Ge Li. "He always pays close attention to the healthcare industry and the well-being of Chinese people. WuXi will continue to strengthen our platform to enable more companies, organizations and entrepreneurs to discover and develop better therapeutic products for patients."
Premier Li's visit highlights WuXi's leadership in China's life science industries. It also highlights the role of innovation in fostering the country's growth and improving quality of life for Chinese patients. China's strategic investment in healthcare aims to make available more effective and affordable treatments for diseases prevalent in the Chinese population, and WuXi strives to become the partner-of-choice for its global collaborators to bring more innovative products to the fastest growing China healthcare market.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners shorten the cycle and lower the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Ronald Aldridge (for investors)
Aaron Shi (for the media)
SOURCE WuXi PharmaTech (Cayman) Inc.